Abstracts by key term: Gesundheitspolitik
Ausgaben für pharmazeutische Innovationen werden weitgehend als Kosten gesehen – und das umso mehr, je größer die Finanzprobleme in der GKV sind. So werden auch im ersten Bericht der Finanzkommission Gesundheit vom 30. März 2026 Arzneimittel als Kostentreiber gesehen.1 Auch der Kabinettsentwurf für ein GKV-Beitragssatzstabilisierungsgesetz (BStabG) verfällt in alte Muster und sieht deutliche Einsparungen bei […]
03.08.2026
Health care research and health care reality are closely intertwined. A constituent part of health services research is to analyze, evaluate and contribute to optimization of the reality of care. This is particularly important in the context of statutory health insurance. The implementation and optimization of care models is one of the core tasks of a health insurance company. Scientific evidence and health care management thus form a quasi-natural unit. The implementation of the findings from health services research into everyday care provides a direct benefit for those insured by the health insurance company as well as for the statutory health insurance.
24.02.2012
Cost-effectiveness analysis has experienced enormous growth in recent years as an aid to decision-making. Their legal anchoring in the performance audit means that the reliability of the statements must be checked. Political and methodological skepticism is particularly directed against a simple decision based on the monetary costs per QALY of a therapy. The discussion is also growing as to whether subjective assessments of benefits by individuals should take precedence over objective assessments of a group. It is still unclear which controls will ultimately be chosen in the healthcare system. However, both approaches require methodological refinement before they can offer helpful support to health policy.